Kappa-晒化卡拉胶对实验动物的抗心律失常作用

Kappa-硒化卡拉胶是一含硒有机化合物。ip 9 mg·kg^-1·d^-1×5d或单次ig 35,70,140mg·kg^-1能显著提高乌头碱致大鼠HA的阈剂量,此作用可与Na₂SeO₃ 1 mg·kg^-1·d^-1×5d ip比拟.随着Kappa-硒化卡拉胶ig剂量增加,尚可提高乌头碱所致VE,VT和VF的阈剂量。ip 9mg·kg^-1·d^-1×5 d或ig 70mg·kg^-1能提高BaCl₂致大鼠或哇巴因致豚鼠HA的阈剂量。对BaCl₂致大鼠VF或哇巴因致豚鼠VE的阈剂量,分别在ig70mg·kg^-1与140mg·kg^-1时有提高,而ipNa₂SeO₃ 1 mg·kg^-1·d^-1×5d无此明显影响。     

磷酸喹哌抗实验性心律失常作用

磷酸喹哌(PQP)9mg·kg~(-1)iv明显降低小鼠室颤的死亡率;PQP 18mg·kg~(-1)ip对氯仿诱发小鼠室颤具有保护作用;PQP 6.3mg·kg~(-1)ip显著增加恒速(10mg·L~(-1)·min~(-1)滴注乌头碱引起麻醉大鼠室性早搏(VE)、室性心动过速(VT)、室性纤颤(VF)所需的乌头碱用量;PQP5.4 mg·kg~(-1)iv显著增加恒速(50mg·L~(-1)·min~(-1))滴注哇巴因引起麻醉豚鼠VE、VT和VF所需哇巴因用量;PQP3.36mg·kg~(-1)iv明显缩短肾上腺素诱发家兔室性心律失常的持续时间.结果表明PQP具有抗心律失常作用。小鼠PQPLD_(50)iv为93.33 mg·kg~(-1)。     

富硒酵母对免疫功能低下小鼠DTH的影响

本文采用环磷酰胺(Cy)诱导免疫功能低下的DTH模型,观察了富硒酵母对DTH的影响.结果发现,Sey(30,60,90mg·kg~(-1)·d~(-1)×6d,ig)对Cy抑制的小鼠DTH有拮抗作用,并能使DTH小鼠低下的脾淋巴细胞ConA增殖反应恢复正常以上;两个较低剂量对Cy所致DTH小鼠免疫器官重量的减轻有抑制作用;两个较高剂量对DTH小鼠低下的脾淋巴细胞LPS增殖反有不同程度的恢复.提示Sey对淋巴细胞的功能有促进作用.     

缬沙坦与福辛普利对儿茶酚胺诱导的心肌肥厚的影响(英文)

目的:研究血管紧张素Ⅱ受体拮抗剂缬沙坦和新型血管紧张素转化酶抑制剂福辛普利对心肌肥厚的影响.方法:SD大鼠ip去甲肾上腺素1.5 mg·kg~(-1)·d~(-1)×15 d,造成心肌肥厚模型.缬沙坦ig 15 mg· kg~(-1)·d~(-1)×15 d,福辛普利ig 30 mg·kg~(-1)·d~(-1)×15 d.测量心重指数,心肌胶原含量,肌球蛋白ATP酶及细胞膜和线粒体Na~ ,K~ -ATP酶,Ca~(2 )-ATP酶的活性,并检测此模型中心肌细胞的凋亡水平.结果:缬沙坦和福辛普利均能阻止心肌肥厚的发生,减少胶原合成,提高肌球蛋白ATP酶及细胞膜和线粒体Na~ ,K~ -ATP酶、Ca~(2 )-ATP酶的活力,抑制心肌细胞的凋亡.结论:缬沙坦和福辛普利可防止儿茶酚胺诱导的心肌重塑,心肌细胞凋亡可能在儿茶酚胺诱导的心肌重塑中起重要作用.     

13-正丙基巴马汀的抗心律失常作用

iv13—正丙基巴马汀(13—n—Ptopyl—Pal-matine)8mg·kg~(-1)能显著减少氯仿诱发小鼠室颤的发生率.提高哇巴因致豚鼠室早、室速、室颤及心搏停止的阈剂量。iv1、3 mg·kg~(-1)可明显减少CaCl_2诱发小鼠心律失常的发生率.缩短BaCl_2诱发大鼠心律失常的持续时间、但对乌头碱诱发大鼠心律失常无明显的对抗作用。此外,13—正丙基巴马汀还能明显提高大鼠心肌细胞膜Na~+,K~+—ATP酶的活性。     

国产尼美舒利的药效学研究

本文研究了国产尼美舒利在小鼠、大鼠及家兔体内的抗炎、镇痛和解热作用.结果表明.尼美舒利抑制巴豆油致小鼠耳廓肿胀(ED_(50)为49.2mg·kg~(-1));抑制角叉菜胶致大鼠足肿(ED_(50)为2.75mg·kg(-1));0.6mg·kg~(-1)剂量对大鼠佐剂关节炎有显著预防和治疗作用。100mg·kg~(-1)对小鼠醋酸扭体法的抑制率为68％;对热板法致痛的痛阈提高率为55％。ip给药对蛋白胨致家兔发热的解热作用.其最小有效剂量为2mg·kg~(-1);5mg·kg~(-1)ig可显著降低啤酒酵母致大鼠升高的体温.证实国产尼美舒利具有很强的抗炎、镇痛和解热作用。     

双嘧达莫抗肿瘤作用的实验研究

给BALB/c和瑞士种实体瘤小鼠ig双嘧达莫(DIP)100、250和500mg·kg~(-1)·d~(-1)×10d.抑瘤率为34.20％～59.26％。ip DIP50和100mg·kg~(-1).对荷瘤C_(57)BL/6小鼠的抑瘤率分别为27.21％和52.18％;对瑞士种小鼠腹水中瘤细胞增殖抑制率为30.77％和48.92％.并能延长腹水瘤小鼠的存活时间。实验表明:DIP对小鼠S_(180)实体瘤和腹水瘤均有明显抑制作用。     

白芍总甙对大白鼠睡眠节律的影响

白芍总甙(TGP)每日ig 50mg·kg~(-1),连续7d可延长正常大鼠慢波睡眠(SWS)的持续时间.并能使咖啡因(12.5 mg·kg~(-1),ip)诱导的失眠大鼠睡眠各参数恢复到接近正常水平。TGP 50mg·kg~(-1)×3d)还可明显延长游泳大鼠(水温25±1℃.游泳时间30min)SWS和异相睡眠的总时间。上述实验结果提示TGP可改善不同功能状态下的大鼠睡眠。     

宫清颗粒诱导Th17/Treg亚群偏移减轻药物流产后子宫出血

目的探讨米非司酮药物流产中Th17/Treg亚群偏移与子宫出血量的相关性及宫清颗粒诱导Th17/Treg亚群偏移减轻药物流产后子宫出血的作用与机制。方法孕小鼠30只,随机分为正常妊娠组和米非司酮大(1.5 mg·kg~(-1)·d~(-1)×3 d,ig)、小剂量组(0.88 mg·kg~(-1)·d~(-1)×3 d,ig),每组10只,改良碱性正铁血红素法检测子宫出血量,流式细胞术双染色法检测子宫组织Th17(CD3~+CD4~+IL-17A~+)、Treg(CD4~+CD25~+Foxp3~+)亚群比例。孕小鼠40只,随机分为米非司酮组(1.5 mg·kg~(-1)·d~(-1)×3 d,ig)和宫清大、中、小剂量组(米非司酮1.5 mg·kg~(-1)·d~(-1)×3 d+宫清颗粒308.16、154.08、77.04 mg·kg~(-1)·d~(-1)×5 d,ig),每组10只,检测子宫出血量及子宫组织Th17、Treg亚群比例,RT-PCR法检测子宫组织白细胞介素-17A(IL-17A)、白细胞介素-10(IL-10)、转化生长因子-β(TGF-β)mRNA转录水平。结果药物流产小鼠子宫出血量与Th17亚群比例、Th17/Treg比值呈负相关(r=-0.700、r=-0.867,P<0.05),与Treg亚群比例呈正相关(r=0.554,P<0.05)。宫清颗粒作用后小鼠子宫出血量明显减少;Th17亚群比例升高,Treg亚群比例降低,Th17/Treg比值升高(均P<0.05);IL-17A mRNA表达升高,IL-10、TGF-βmRNA表达降低,均P<0.05。结论米非司酮药物流产中Th17/Treg亚群偏移与子宫出血量密切相关,宫清颗粒优势诱导Th17亚群偏移,进而减轻子宫出血。     

枸杞多糖对实验性肝损伤小鼠的保护作用

<正> 枸杞多糖(Lycium barbarum polysaccharides,LBP)具有提高正常小鼠和荷瘤小鼠细胞免疫功能的作用,还具有降低老龄小鼠的肝细胞脂质过氧化作用。本文观察了LBP对CCl_4所致小鼠实验性肝损伤的保护作用。 小鼠分成4组,d2 ip CCl_4 100mg·kg~(-1),LBP治疗组于d0～2分别ip5和10mg·kg~(-1)·d~(-1),正常对照     

Nachweis einiger Heilmittel in der Kniegelenksynovialflüssigkeit

Zusammenfassung Mittels Gaschromatographie und Dünschichtchromatographie wiesen die Autoren 11 Substanzen nach, welche durch Injektion oder nach Verabreichung per os in die Kniegelenksynovialflüssigkeit eindrangen. In ihrer Aufstellung konnten sie eine direkte Beziehung zwischen Struktur sowie chemischphysikalischen Eigenschaften der Substanz und ihrer Fähigkeit, aus dem Blut in die Kniegelenksynovialflüssigkeit einzudringen, nicht nachweisen, außer der Tatsache, daß Substanzen mit starker Affinität zu Eiweißstoffen erst in höheren Dosen nachweisbar waren.     

Synthesis,Cytotoxicity and Antileishmanial Activity of Some N-(2-(indol-3-yl)ethyl)-7-chloroquinolin-4-amines

We report herein the condensation of 4,7-dichloroquinoline (1) with tryptamine (2) and D-tryptophan methyl ester (3) . Hydrolysis of the methyl ester adduct (5) yielded the free acid (6) . The compounds were evaluated in vitro for activity against four different species of Leishmania promastigote forms and for cytotoxic activity against Kb and Vero cells. Compound (5) showed good activity against the Leishmania species tested, while all three compounds displayed moderate activity in both Kb and Vero cells.     

Emerging drugs for epilepsy

Epilepsy affects ≤ 1% of the world's population. Antiepileptic drugs (AEDs) are the mainstay of treatment, although more than a third of patients are not rendered seizure free with existing medications. Uncontrolled epilepsy is associated with increased mortality and physical injuries, and a range of psychosocial morbidities, posing a substantial economic burden on individuals and society. Limitations of the present AEDs include suboptimal efficacy and their association with a host of adverse reactions. Continued efforts are being made in drug development to overcome these shortcomings employing a range of strategies, including modification of the structure of existing drugs, targeting novel molecular substrates and non-mechanism-based drug screening of compounds in traditional and newer animal models. This article reviews the need for new treatments and discusses some of the emerging compounds that have entered clinical development. The ultimate goal is to develop novel agents that can prevent the occurrence of seizures and the progression of epilepsy in at risk individuals.     

盐酸达泊西汀中甲磺酸甲酯、甲磺酸乙酯及甲磺酸异丙酯的顶空毛细管GC-ECD法测定

建立了衍生化顶空毛细管气相色谱-电子捕获检测器(ECD)法测定盐酸达泊西汀中的甲磺酸甲酯(MMS)、甲磺酸乙酯(EMS)和甲磺酸异丙酯(IMS).应用碘化钠衍生技术,使用PW-5毛细管柱,载气为氮气,ECD检测,程序升温.MMS、EMS和IMS分别在0.03～0.30、0.05～0.50和0.05～0.50 μg/ml浓度范围内线性关系良好,平均回收率分别为63.5％、100.3％和96.2％,最低检测限分别为0.30、0.50和0.50 ng/ml.     

Lung disease and PKCs

The lung offers a rich opportunity for development of therapeutic strategies focused on isozymes of protein kinase C (PKCs). PKCs are important in many cellular responses in the lung, and existing therapies for pulmonary disorders are inadequate. The lung poses unique challenges as it interfaces with air and blood, contains a pulmonary and systemic circulation, and consists of many cell types. Key structures are bronchial and pulmonary vessels, branching airways, and distal air sacs defined by alveolar walls containing capillaries and interstitial space. The cellular composition of each vessel, airway, and alveolar wall is heterogeneous. Injurious environmental stimuli signal through PKCs and cause a variety of disorders. Edema formation and pulmonary hypertension (PHTN) result from derangements in endothelial, smooth muscle (SM), and/or adventitial fibroblast cell phenotype. Asthma, chronic obstructive pulmonary disease (COPD), and lung cancer are characterized by distinctive pathological changes in airway epithelial, SM, and mucous-generating cells. Acute and chronic pneumonitis and fibrosis occur in the alveolar space and interstitium with type 2 pneumocytes and interstitial fibroblasts/myofibroblasts playing a prominent role. At each site, inflammatory, immune, and vascular progenitor cells contribute to the injury and repair process. Many strategies have been used to investigate PKCs in lung injury. Isolated organ preparations and whole animal studies are powerful approaches especially when genetically engineered mice are used. More analysis of PKC isozymes in normal and diseased human lung tissue and cells is needed to complement this work. Since opposing or counter-regulatory effects of selected PKCs in the same cell or tissue have been found, it may be desirable to target more than one PKC isozyme and potentially in different directions. Because multiple signaling pathways contribute to the key cellular responses important in lung biology, therapeutic strategies targeting PKCs may be more effective if combined with inhibitors of other pathways for additive or synergistic effect. Mechanisms that regulate PKC activity, including phosphorylation and interaction with isozyme-specific binding proteins, are also potential therapeutic targets. Key isotypes of PKC involved in lung pathophysiology are summarized and current and evolving therapeutic approaches to target them are identified.